86663020 - ADAPTIVE THERAPEUTICS

Information

• Trademark
• 86663020

• Source

• Serial Number

  86663020

• International Classifications

  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  June 15, 2015
  9 years ago

• Transaction Date

  February 14, 2018
  6 years ago

• Status Date

  April 27, 2016
  8 years ago

• Location Date

  April 27, 2016
  8 years ago

• Status Code

  602

• Current Location

  TMEG LAW OFFICE 101 - EXAMINING ATTORNEY ASSIGNED

  Employee Name

  PEREZ, STEVEN M

• Attorney Docket Number

  10214-00502-

  Attorney Name

  Hoang-chi Truong

  Law Office Assigned Location Code

  L10

• Owners

  • Adaptive Biotechnologies Corporation

Case File Statements

• GS0421: Scientific and technological services and research and design relating thereto; scientific research, development, engineering, testing, scientific research consultation, and analytical services in the fields of medicine, oncology, hematology, auto-immune disorders, infectious diseases, immunology, immunotherapies, immunopharmaceuticals, immune sequencing, immune repertoire quantitation and sequencing, diagnostics, pharmaceuticals, genetics, gene expression, genetics testing, vaccines and vaccine development, biotechnology, T-cell therapeutics, antibody development and therapeutics, and therapeutic technologies; development of new technology for others in the fields of medicine, oncology, hematology, auto-immune disorders, infectious diseases, immunology, immunotherapies, immunopharmaceuticals, immune sequencing, immune repertoire quantitation and sequencing, diagnostics, pharmaceuticals, genetics, genetics testing, vaccines and vaccine development, biotechnology, T-cell therapeutics, antibody development and therapeutics, and therapeutic technologies; DNA screening and analysis services; genome amplification; genotyping services for research or analysis purposes; medical and scientific research in the fields of cancer biology and diagnosing and treating cancer; providing medical and scientific research information in the field of clinical trials; scientific research in the field of relative and absolute quantitation of adaptive immune cells in a complex biological sample; scientific research for providing relative and absolute quantitation of adaptive immune cells in a solid tumor sample; scientific research for estimating the relative representation of tumor infiltrating T cells in a solid tumor; scientific research for quantifying the presence and clonality of tumor infiltrating lymphocytes in solid tumors; research and development for quantifying the presence and clonality of tumor infiltrating lymphocytes in solid tumors; scientific research, development, engineering, testing, and analytical services for identifying polypeptide pairs of adaptive immune receptor heterodimers of the immune system; scientific research, development, engineering, testing, and analytical services for analyzing and quantifying the diversity of the immune system; scientific research, development, engineering, testing, and analytical services for discovering immune targets; scientific research, engineering, testing, and analytical services for developing monoclonal antibodies and epitope mapping; scientific research for providing sequencing data and analysis of the immune system for vaccine development and vaccine optimization; research and development of vaccines, immunotherapies, and diagnostics; providing technology consultation and research services in the field of immune repertoire analysis, personalized medicine, vaccines, immunotherapies, and diagnostics; scientific research for providing computational analysis of the immune repertoire; providing clinical diagnostic assays and diagnostic or prognostic testing for detection of minimal residual disease in lymphoid malignancies; providing analysis, evaluation, and clinical reports of a patient's immune repertoire, including T cell or B cell clonal diversity and clone frequency; providing assays for tracking clones in an immune repertoire over time; providing diagnostic assays and diagnostic or prognostic testing for residual disease, and the analysis, evaluation, and reports of those test results to help healthcare professionals determine a patient's clinical diagnosis, prognosis or treatment, to assess the effectiveness of patient treatments, and to revise future treatments accordingly; research, development, engineering, testing, and analytical services in the fields of vaccines, screening and detecting diseases, medicine, and therapeutics; research and development of vaccines, immunotherapies, medical diagnostics kits, and therapeutics; research and development of diagnostic test kits for screening and detecting diseases; laboratory research and testing services relating to vaccines, screening and detecting diseases, medicine, and therapeutics; computer services; design and development of computer hardware and software; computer services, namely, software as a service (SAAS) services featuring software that provides information, test results for screening and detecting diseases, and the analysis, evaluation, and reporting of those test results to healthcare professionals and patients; research and diagnostic services for identifying antigen-specific T cells for therapeutic use
• GS0441: Medical services; medical analysis and diagnostic services; medical diagnostic services, namely, medical testing for diagnostic or treatment purposes; medical diagnostic services, namely, medical diagnostic testing, monitoring and reporting services; providing medical diagnostic testing for the treatment of cancer; providing medical testing for immune responses to immunotherapy or cancer treatment; providing medical quantitative analysis and testing services in the fields of cancer biology, immunology, pharmaceuticals and vaccines for diagnostic or treatment purposes; medical testing for the prognosis and staging of patients with solid tumors for treatment purposes; therapeutic services; therapeutic services for the treatment of diseases; therapeutic services for the treatment of cancer

Case File Event Statements

• 2/13/2018 - 6 years ago

  9 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 4/27/2016 - 8 years ago

  8 - ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Type: MAB2

• 4/27/2016 - 8 years ago

  7 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2

• 9/30/2015 - 9 years ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 9/30/2015 - 9 years ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 9/30/2015 - 9 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 9/23/2015 - 9 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 6/18/2015 - 9 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 6/18/2015 - 9 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP